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1. Introduction 
Posterior Chamber Phakic Toric Implantable Collamer Lenses have become increasingly 
used to correct refractive error associated with astigmatism. These devices are claimed to 
provide high efficacy in terms of refractive correction. This book chapter is an updated 
review on the safety and effectiveness and potential complications of the toric implantable 
collamer lens (Toric ICL) published in peer-review literature. 
Toric implantable collamer lens (Toric ICL) from Staar Surgical Inc., Monrovia, CA, is a 
posterior chamber phakic intraocular lens that has been demonstrated to provide safe, 
effective, predictable and stable visual and refractive outcomes among various refractive 
ranges of ammetropia1-4. The present review will focus on the use of Toric ICL in the 
treatment of myopic astigmatism in normal eyes as well as in eyes with keratoconus, 
pellucid marginal degeneration, after keratoplasty, and also as a secondary piggyback lens. 
2. Toric ICL in normal astigmatic eyes 
The clinical outcomes of the U.S. FDA TICL clinical trial5 has been published supporting the 
efficacy and predictability of the TICL in the treatment of myopic astigmatism up to -4.00 
diopters (D). In this study, two hundred ten eyes of 124 patients with pre-operative myopia 
between 2.38 and 19.5 D (spherical equivalent) and 1 to 4 D of astigmatism were enrolled. 
They analyzed the uncorrected visual acuity (UCVA), refraction, best spectacle-corrected 
visual acuity (BSCVA), adverse events, and postoperative complications. At 12 months post-
operatively, the proportion of eyes with 20/20 or better UCVA (83.1%) was identical to the 
proportion of eyes with preoperative 20/20 or better BCVA (83.1%); 76.5% had 
postoperative BCVA better than or equal to preoperative BCVA. The mean manifest 
refractive cylinder dropped from 1.93 ± 0.84 at baseline to 0.51 ±0.48 D postoperatively, a 
73.6% decrease in astigmatism. Mean spherical equivalent refraction improved from -
9.36±2.66 D preoperatively to 0.05±0.46 D postoperatively. A total of 76.9% of eyes were 
predicted accurately to within ±0.5D, 97.3% to within ±1.0 D, and 100% to within ±2.0 D of 
predicted spherical equivalent. Postoperatively, 37.6% of eyes had a BCVA of 20/12.5 or 
better, compared with a preoperative level of 4.8%. BCVA of 20/20 or better occurred in 
96.8% postoperatively, compared with 83.1% preoperatively. Mean improvement in BCVA 
was 0.88 lines; there were 3 cases (1.6%) that lost ≥2 lines of BCVA, whereas 18.9% of cases 
improved by ≥2 lines. A total of 76.4% of cases gained ≥1 lines of BCVA, whereas only 7.5% 
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of cases lost the equivalent amount (Fig. 1). Three ICL removals were performed without 
significant loss of BCVA, and 1 clinically significant-lens opacity was observed. They 
concluded that their results support the efficacy and predictability of Toric ICL implantation 
to treat moderate to high myopic astigmatism, without identifying important safety 
concerns during the follow-up. 
 
Fig. 1. Safety: Changes in Lines of vision (BCVA) before and after 12 months of Toric ICL 
Implantation 
Kamiya et al.6 have also analyzed the outcomes of the Toric ICL being compared with 
wavefront-guided laser in situ keratomileusis (LASIK) in high myopic astigmatism. They 
studied 30 eyes (18 patients) having Toric ICL implantation and 24 eyes (17 patients) having 
wavefront-guided LASIK (Technolas 217z) to correct high myopic astigmatism (spherical 
equivalent ≤-6.0D; refractive cylinder r≥1.0 D). At 6 months, the mean safety index was 
1.28±0.25 in the Toric ICL group and 1.01±0.16 in the LASIK group and the mean efficacy 
index, 0.87±0.15 and 0.83± 0.23, respectively. All eyes in the Toric ICL group and 71% of eyes 
in the LASIK group were within ±1.00 D of the targeted spherical equivalent correction. The 
mean change in manifest refraction from 1 week to 6 months was -0.04±0.24 D in the Toric 
ICL group and -0.60±0.49 D in the LASIK group. There were no significant complications in 
the Toric ICL group; 2 eyes (8.3%) in the LASIK group required enhancement ablations. 
They concluded that Toric ICL implantation was better than wavefront-guided LASIK in 
eyes with high myopic astigmatism in almost all measures of safety, efficacy, predictability, 
and stability, suggesting that Toric ICL implantation may become a viable surgical option to 
treat high myopic astigmatism. 
Following a comparison from Kamiya et al.6, Choi et al.7 compared the results between Toric 
ICL and bioptics (ICL + excimer laser ablation) for the correction of myopic astigmatism. 
They performed a retrospective evaluation in 29 eyes (20 patients) with Toric ICL 
implantation and 26 eyes (17 patients) treated with bioptics. For eyes treated with bioptics, 
corneal ablation was performed at 1.5 to 5 months (mean 2.56 months) after ICL 
implantation by laser epithelial keratomileusis in 17 eyes, LASIK in 8 eyes, and 
photorefractive keratectomy in 1 eye. UCVA, BCVA, refraction, adverse events, safety, and 
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efficacy were assessed preoperatively and 1, 6, and 12 months postoperatively. At 1 month 
postoperatively, UCVA in the Toric ICL group was significantly higher than in the bioptics 
group (P=.02). However, the difference in UCVA at 12 months was not significant. At 12 
months, mean spherical equivalent refraction was 0.33±0.21 D in the Toric ICL group and 
0.29±0.41 D in the bioptics group (P=.07). Mean astigmatic error was higher in the Toric ICL 
group (-0.42±0.32 D) than in the bioptics group (-0.32±0.38 D) (P=.10). In the bioptics group, 
the mean refractive cylinder at 12 months decreased from that reported at 6 months because 
of retreatment performed in two eyes. Safety and efficacy were not statistically different 
between groups. One eye with a Toric ICL was treated to correct lens decentration and two 
crystalline lens opacities were observed after bioptics. They concluded that Toric ICL 
implantation provides reliable visual outcomes similar to bioptics and that the advantages 
of Toric ICL implantation are a more stable visual outcome and the elimination of laser 
treatments and their inherent risks.  
Bhikoo et al.8 reported their outcomes at 12-months follow-up in 77 eyes with moderate to 
high myopic astigmatism who underwent Toric ICL implantation. The preoperative mean 
spherical equivalent ranged from -2.50D to -15.00 D of myopia and from 1.00 D to 7.00 D 
of astigmatism. At 12 months, mean manifest refractive cylinder decreased 81% from 2.38 
D to 0.44 D. Mean manifest refractive cylinder within 1.00 D occurred in 99% (76/77) of 
eyes, whereas 86% (66/77) was within 0.75 D. 99% (76/77) had postoperative BCVA better 
than or equal to preoperative values, whereas 78% (60/77) gained up to one line BCVA 
and 1% (1/77) lost one line BCVA. Uncorrected binocular vision of 6/6 or better occurred 
in 90% (38/42) of patients compared with binocular BCVA of 6/6 or better in 67% (28/42) 
preoperatively. One ICL was replaced due to low vaulting and two eyes with astigmatism 
of 3.25 D and 3.50 D received subsequent LASIK to reduce residual small refractive errors. 
Indications for ICL were: myopia too high for LASIK (73%), cornea too thin for LASIK 
(44%) and contact lens intolerance (33%). Night halos were reported in 10% (8/77) of eyes 
at 12 months, one ICL was removed due to unrecognized preoperative glaucoma and 
there were no cases of cataract formation, or endophthalmitis. They concluded that the 
outcome supports the safety, efficacy and predictability of Toric ICLs to treat myopic 
astigmatism. 
In a recent study, Kamiya et al.9 assessed the 1-year clinical outcomes of Toric ICL 
implantation for moderate to high myopic astigmatism in 56 eyes of 32 consecutive patients, 
with spherical equivalent errors of -4.00 to -17.25 D and cylindrical errors of -0.75 to -4.00 D. 
They analyzed UCVA, BCVA, safety index, efficacy index, predictability, stability, adverse 
events and measured the higher order aberrations (HOAs) and the contrast sensitivity 
function. LogMAR UCVA and BCVA were -0.11±0.12 and -0.19±0.08 1 year after surgery, 
respectively. The safety and efficacy indices were 1.17±0.21 and 1.00±0.29 with 91% and 
100% of the eyes within 0.5 and 1.0 D, respectively, of the targeted correction. Manifest 
refraction changes of -0.07±0.27 D occurred from 1 week to 1 year. For a 4-mm pupil, fourth-
order aberrations were changed, not significantly, from 0.05±0.02 μm before surgery to 
0.06±0.03 μm after surgery (P = 0.38). Similarly, for a 6-mm pupil, fourth-order aberrations 
were not significantly changed, merely from 0.20 ± 0.08 μm before surgery to 0.23 ± 0.11 μm 
after surgery (P = 0.15). The area under the log contrast sensitivity function was significantly 
increased from 1.41 ± 0.15 before surgery to 1.50 ± 0.13 after surgery (P < 0.001). No vision-
threatening complications occurred during the observation period. They concluded that in 
their experience, the Toric ICL performed well in correcting moderate to high myopic 
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astigmatism during a 1-year observation period, suggesting its viability as a surgical option 
for the treatment of such eyes. 
Alfonso et al.10 analyzed their outcomes with the lens in 55 eyes; assessment included 
UCVA, BCVA, refraction, vault and adverse events 12 months post-surgery. Preoperatively, 
the mean sphere in the 55 eyes was -4.65± 3.02 D (range -0.50 to -12.50 D) and the mean 
cylinder, -3.03±0.79 D (range -1.25 to -4.00 D). At 12 months, the mean Snellen decimal 
UCVA was 0.80±0.20 and the mean BCVA, 0.85±0.18; 62.0% of eyes had a BCVA of 20/20. 
More than 50.0% of eyes gained 1 or more lines of BCVA. The treatment was highly 
predictable for spherical equivalent (r2 = 0.99) and astigmatic components J0 (r2 = 0.97) and 
J45 (r2 = 0.99). Of the eyes, 94.5% were within ± 0.50 D of the attempted spherical equivalent 
and all were within ±1.00 D. For J0, 94.5% of eyes were within ±0.50 D and for J45, 98.2% of 
eyes; all eyes were within ± 1.00 D. The efficacy index was 0.95 at 3 months and 1.08 at 1 
year. They concluded that the UCVA and BCVA with the Toric ICL were good and highly 
stable over 12 months, confirming the procedure is safe, predictable, and effective for 
correction of moderate to high astigmatic. Similarly, they also analyzed the outcomes for 
eyes with preoperative cylinder values higher than 4.00D11. The study included 15 eyes of 12 
patients (9 women). Preoperatively, the mean manifest spherical refraction was -1.98 D±1.32 
(range -0.50 to -5.50 D) and the mean refractive cylinder, -4.85±0.83 D (range -6.50 to -4.00 
D). At 12 months, the mean refractive cylinder was -0.55±0.52 D (range -1.50 to 0.00 D), with 
93.3% of eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -
0.31±0.42 (range -1.00 to 0.75 D), with more than 70% of eyes within ±0.50 D of the target. 
For the astigmatic components, 93.3% of eyes were within ±1.00 D of J0 (r2 = 0.98) and all 
eyes were within ±1.00 D of J45 (r2 = 0.98). The mean UCVA was 0.70±0.20 and the mean 
BCVA, 0.83±0.12, bieng the overall efficacy index 0.90. Postoperatively, all eyes had 
unchanged BCVA or gained 1 or more lines. They consluded, that the refractive outcomes 
and improvement in UCVA and BCVA were rapidly achieved and remained fairly 
consistent throughout the follow-up period, supporting the use of TICL in eyes with high 
astigmatism. 
In a recent paper, Mertens12 assessed the predictability, efficacy, safety and stability in 
patients who received a Toric ICL to correct moderate to high myopic astigmatism. He 
studied 43 eyes of 23 patients with a mean spherical refraction of −4.98 ± 3.49 D (range: 0 to 
−13 D), and a mean cylinder of −2.62 ± 0.97 D (range: −1.00 to −5.00 D). Main outcomes 
measures evaluated during a 12-month follow-up included UCVA, refraction, BCVA, vault, 
and adverse events. At 12 months the mean Snellen decimal UCVA was 0.87 ± 0.27 and 
mean BCVA was 0.94 ± 0.21, with an efficacy index of 1.05. More than 60% of the eyes 
gained ≥1 line of BCVA (17 eyes, safety index of 1.14). The treatment was highly predictable 
for spherical equivalent (r2 = 0.99) and astigmatic components: J0 (r2 = 0.99) and J45 (r2 = 0.90) 
(Fig.2). The mean spherical equivalent dropped from −7.29 ± 3.4 D to −0.17 ± 0.40 D at 12 
months. Of the attempted spherical equivalent, 76.7% of the eyes were within ±0.50 D and 
97.7% eyes were within ±1.00 D, respectively. For J0 and J45, 97.7% and 83.7% were within 
±0.50 D, respectively. He concluded that the outcomes of the study support the safety, 
efficacy, and predictability of Toric ICL implantation to treat moderate to high myopic 
astigmatism. 
In addition, it should be considered that custom-designed Toric ICL may correct large 
sphero-cylindrical refractive errors. Mertens et al.13 reported a case of a 40-year-old woman 
with high astigmatism and thin corneas who underwent bilateral custom-designed Toric 
ICL implantation. The appropriate Toric ICL power was calculated to be -8.00 +8.00 x 96° for 
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Fig. 2. Preoperative versus  12 month postoperative best corrected visual acuity (BCVA) 
after Toric implantable collamer lens implantation. Clinical Ophthalmology 2011:5 369-375 
the right eye and -8.50 +7.50 x 86° for the left eye with an optical zone of 5.5 mm and 6.875 
mm at the corneal plane. Their results, at 3 and 6 months postoperatively, showed that 
UCVA and DCVA of both eyes improved to 20/20 and 20/16, respectively. At 19 months, 
UCVA was 20/20 and 20/16 in the right and left eyes, respectively, and BCVA had 
improved to 20/16 and 20/10, respectively. The subjective refraction was stable, with a 
change of -0.37±0.17 D from preoperative to 19 months postoperatively. Throughout the 
postoperative period, iridotomies remained patent and the corneas were clear. They 
concluded that bilateral implantation of the custom-designed Toric ICL successfully 
corrected the patient's high astigmatism. Preoperative subjective refractive cylinder of -5.25 
x 6° in the right eye and -5 x 176° in the left eye changed to -0.5 x 77 degrees and -0.5 x 115°, 
respectively, after Toric ICL implantation. There was almost no change in corneal 
astigmatism. This customized approach led to UCVA of 20/20 in the right eye and 20/16 in 
the left eye, and DCVA of 20/16 in the right eye and 20/10 in the left eye.  
Mertens described the importance of preoperative marking of the eye’s horizontal axis prior 
to Toric ICL implantation12-13 (Fig. 3). This axis would be the reference for later alignment of 
the lens to the target axis (Fig 4). When doing so intra-operatively, the surgeon must pay 
attention to use the entrance pupil as a reference for axis marking instead of the geometrical 
center of the cornea, thus avoiding undesired edge glare and induced coma and other 
secondary aberrations. Postoperatively, the vaulting of the Toric ICL can be easily assessed 
with the slit lamp (Fig. 5) 
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Fig. 3. Preoperative marking of the eye‘s horizontal axis prior to Toric ICL implantation 
 
 
Fig. 4. Yellow line indicates lens horizontal axis connecting the 2 diamond-shaped marks of 
the Toric ICL. The arrows indicate that the surgeon aligned the lens at 5° CCW from the 
horizontal meridian. 
3. TICL in eyes with keratoconus 
In keratoconic eyes in which keratorefractive or other alternative refractive procedures were 
not a good or feasible option, Toric ICL implantation showed promising results. In this case, 
for example, Coskunseven et al.14 evaluated the results of combined Intacs (Addition  
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Fig. 5. Two white arrows: Clearance from the Toric ICL (red arrow) and the crystalline lens 
(*) is assessed with the slit-lamp. An optical section focused on the implant will allow the 
surgeon to observe the Toric ICL-lens space (vault). 
Technology, Fremont, CA) and the TICL implantation in keratoconic patients with extreme 
myopia and irregular astigmatism. They reported the outcomes in three eyes of two 
consecutive highly myopic keratoconic patients who had undergone Toric ICL implantation 
after Intacs procedure. Implantation of the Toric ICLs was performed at intervals between 
six and 10 months after Intacs procedure. They did not encounter intraoperative or 
postoperative complications. An improvement in UCVA and DCVA was found after  Intacs 
and TICL procedures in all eyes. All eyes were within 1 D of emmetropia, whereas the mean 
manifest refractive spherical equivalent refraction decreased from -18.50±2.61 D (range, -
16.75 to -21.50 D) to 0.42 D (range, 0 to -0.75 D). The mean difference between preoperative 
and last follow-up UCVA and BCVA was a gain of 6.67±1.15 lines (ranging from six to eight 
lines) and 4.33± 2.52 lines (ranging fromof two to seven lines), respectively. They concluded 
that combined Intacs and Toric ICL implantation in a two-step procedure is an effective 
method for correcting keratoconic patients with extreme myopia. 
Kamiya et al.15 showed two patients in whom Toric ICL have been effective for the 
correction of high myopic astigmatism with stable keratoconus. Both patients had a history 
of contact lens intolerance, and refraction and corneal topography were stable for 3 to 4 
years. Preoperatively, the manifest refraction was -10.00 -6.00 x 100° in case 1 and -8.00 -2.75 
x 100° in case 2. Postoperatively, the manifest refraction was +0.50 -1.00 x 90° in case 1 and -
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0.25 -1.25 x 100° in case 2. UCVA and BCVA were markedly improved after implantation in 
both patients without progressive sign of keratoconus during 1-year follow-up. They 
concluded that Toric ICL implantation may be an alternative for the correction of high 
myopic astigmatism in eyes with stable keratoconus. Recently, the authors have increased 
the sample size16. In a new study they evaluated 27 eyes of 14 patients with spherical 
equivalents of -10.11 ± 2.46 D and astigmatism of -3.03±1.58 D who underwent Toric ICL 
implantation for mild keratoconus. LogMAR UCVA and LogMAR BCVA were -0.09 ± 0.16 
and -0.15 ± 0.09 respectively, 6 months after surgery. The safety and efficacy indices were 
1.12 ± 0.18 and 1.01 ± 0.25. At 6months, 85% and 96% of the eyes were within ±0.5 and ±1.0 D 
respectively of the targeted correction. No vision-threatening complications occurred during 
the observation period. They again concluded that Toric ICL implantation was good in all 
measures of safety, efficacy, predictability, and stability for the correction of spherical and 
cylindrical errors in eyes with early keratoconus, suggesting its viability as a surgical option 
for the treatment of such eyes.  
Alfonso et al.17 also implanted the Toric ICL in 30 keratoconic eyes (21 patients) with a mean 
myopia of -5.38±3.26 D (range -13.50 to -0.63 D) and a mean cylinder of -3.48±1.24 D (range -
1.75 to -6.00 D). At 12 months, 86.7% of the eyes were within ±0.50 D of the attempted 
refraction and all eyes were within ±1.00 D. For the astigmatic components J0 and J45, 83.3% 
of eyes and 86.7% of eyes, respectively, were within ±0.50 D. The mean Snellen UCVA was 
0.81±0.20 and the mean BCVA, 0.83±0.18; BCVA was 20/40 or better in 29 eyes 96.7% of eyes 
and 20/25 or better in 22 eyes (73.3%). No eyes lost more than 2 lines of BCVA; 29 eyes 
(96.7%) maintained or gained 1 or more lines being the efficacy index of 1.07 and the safety 
index, 1.16. There were no complications or adverse events concluding that Toric ICL 
implantation is a predictable, effective procedure to correct ametropia in eyes with 
keratoconus.  
4. Toric ICL after penetrating keratoplasty 
The use of the Toric ICL after penetrating keratoplasty has been also proposed. Alfonso et 
al.18, evaluated the efficacy, predictability, and safety of Toric ICL after this technique in 15 
eyes that had preoperative myopia ranging from -2.00 to -17.00 D or astigmatism from -1.50 
to -7.00 D. Twenty-four months postoperatively, the mean Snellen decimal UCVA was 
0.51±0.30. The UCVA was 20/40 or better in 7 eyes (46.6%) and the mean BCVA was 
0.79±0.22. The BCVA was 20/40 or better in 12 eyes (80%) and 20/25 in 6 eyes (40%). No eye 
lost more than 1 line of acuity, 2 eyes gained 1 line, and 5 eyes gained more than 2 lines; 8 
eyes were unchanged, being the safety index 1.58. The spherical equivalent was within ±1.00 
D in 80% of eyes and within ±0.50 D in 66.6% of eyes, with a mean postoperative value of -
0.95±1.12 D. At 24 months, the mean endothelial cell loss was 8.1%. they concluded that the 
results found indicate that Toric ICL is a viable treatment for myopia and astigmatism after 
penetrating keratoplasty in patients for whom glasses, contact lenses, or corneal refractive 
surgery are contraindicated. 
A case report of Akcay et al.19 also adds valuable literature to this application. They describe 
that the patient's manifest refraction improved from -8.0 -1.75 x 170° preoperatively, with an 
UCVA of 0.15 and a BCVA of 0.4, to +0.75 -0.50 x 130° postoperatively, with a UCVA of 0.8 
and a BCVA of 1.0. No serious complications or refractive changes occurred during the 1-
year follow-up concludind that implantation of a myopic TICL in phakic eyes is an option to 
correct postkeratoplasty anisometropia and astigmatism.  
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5. Toric ICL in eyes with pellucid marginal degeneration 
Kamiya et al.20 have also recently reported a case in which Toric ICL effectively corrected 
the refractive errors of pellucid marginal degeneration. They described preoperatively that, 
in the patient's right eye, the manifest refraction was -10.5 -3.5 x 55°, the UCVA was 
20/1000, and the BCVA was 20/16; in the left eye, the manifest refraction was -11.0 - 6.5 x 
130° and the UCVA and BCVA were 20/1000 and 20/20, respectively. After bilateral 
implantation of a TICL, in the right eye, the manifest refraction was +1.50 - 0.75 x 10°, the 
UCVA was 20/16, and the BCVA was 20/12.5; in the left eye, the manifest refraction was 
+2.5 -3.25 x 125° and the UCVA and BCVA were 20/40 and 20/16, respectively. They did 
not find signs of progressive disease and no vision-threatening complication were observed 
during the 6-months follow-up. They considered that Toric ICL implantation may be a 
viable surgical option for the correction of high myopic astigmatism in eyes with pellucid 
marginal degeneration.  
6. Toric ICL for secondary piggyback 
The last indication that has been considered for the use of Toric ICL is piggyback 
implantation. Kojima et al.21 investigated eight pseudophakic eyes of five patients who 
underwent piggyback insertion of a Toric ICL to correct residual refractive error. The results 
showed that pre- and 6-month postoperatively logMAR UCVA were 0.759±0.430 and 
0.201±0.458, respectively, with all eyes within ±0.50 D of intended spherical equivalent 
refraction and refractive astigmatism within ±0.50 D in five (62.5%) eyes and ±1.00 D in 
seven (87.5%) eyes. No eyes lost more than one line of BCVA and pupillary block occurred 
in one eye on postoperative day 1. They concluded that piggyback insertion of a Toric ICL 
appears to be effective and predictable in correcting refractive error in pseudophakic eyes. 
7. Complications and adverse events with Toric ICL 
Sanders et al. 5 reported secondary surgical interventions in 5 eyes (2.4%) in the Toric ICL 
study cohort. In 3 eyes the ICL was removed, in one case due to PI-related visual symptoms, 
in the second case due to trace anterior subcapsular opacity and in the last case due to over-
sizing and induced anisocoria. One eye had the ICL replaced with a smaller diameter ICL 
and another eye had a repositioning due to surgical misalignment. 
In a more recent study, Kamiya K et al9 reported secondary surgical interventions in five 
eyes (8.9%). These eyes required repositioning of the lens very early post-operatively, 
ranging from one day to one week due to off-axis alignment. Two eyes required late 
repositioning due to off-axis secondary to a traumatic event. Finally, three eyes developed 
asymptomatic subcapsular opacity, none of them requiring an ICL removal because there 
was no impact on BCVA. Otherwise they reported no cases on pigment dispersion, 
pupillary block or other vision-threatening complications during their follow-up period. 
Reported adverse events related to Toric ICL are those applicable to ICL in addition to early 
surgical misalignment and rotation of the implant. Careful marking of the eye’s axis and 
attention to marking the target axis are essential to ensure proper surgical alignment of the 
Toric ICL. Lens rotations may occur if the lens is too short for the eye’s anatomy and in these 
cases an exchange for a longer diameter ICL should resolve the problem. In rare instances, 
an optimally vaulting lens may be found off-axis post-operatively; Navas et al22 found that 
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repositioning of the lens back to target axis when the vault is optimal yield a satisfactory 
outcome in their case study. 
Most common complications and adverse events reported with the ICL platform in general 
include: early replacements due to sizing issues (under- or over-sizing), lens repositioning 
(surgical misalignment or true early rotation, late rotation), development of anterior sub-
capsular opactity which becomes clinically significant requiring lens removal and cataract 
surgery, pupillary block and/or angle closure with elevated IOP due to non functioning 
peripheral iridotomies (PIs), (too small, too peripheral, occluded or narrowed), and to a 
lesser extent symptoms of glare/halos or lines coming from the peripheral iridotomies or 
from the smaller optical zone related to the patient’s mesopic pupil diameter. Based on the 
meta-analysis from Chen et al.23 where different ICL lens designs were included (prototype 
and obsolete versions as well as currently available V4 model) the most common 
complication was cataract formation. Several factors involved in cataract development 
discussed in this analysis included age, degree of myopia, low vault, surgical trauma, 
learning curve, steroid use, lens design, pre-existing opacities, trauma and inflammation. 
Several other peer-reviewed articles support the relatively low incidence of complications 
with the ICL. 
In conclusion, Toric ICL has been worldwide used for astigmatism correction showing their 
efficacy, predictability, stability and safety. Toric ICLs are considered an attractive 
approach, based in large part on the phenomenal acceptance of intraocular lenses for not 
only the aphakic or cataract patient but also, recently, the refractive patient. The present 
chapter reviewed the outcomes for normal astigmatic eyes and also those found in different 
keratoconic eyes, post-penetrating keratoplasty, eyes with pellucid marginal degeneration 
and also in pseudophakic eyes with the use ICL as secondary piggyback lens. In general 
terms, the results of Toric ICL implantation from these studies are in agreement confirming 
its predictability, efficacy, together with safety outcomes, making this option as a highly 
reliable alternative in the treatment of moderate to high astigmatism. Then, TICLs are safe 
and effective tools to compensate for different degrees of astigmatism, involving quite low 
risks. 
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